retatrutide clinical trials phase VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide approval: FDA status, clinical

Phase 2 trials test a drug on a few hundred participants over a year or so to establish efficacy and identify side effects

The record needs to explicitly confirm that the patient is currently on a prescribed, ongoing insulin regimen

Subsequent studies confirmed that liraglutide significantly improved PASI scores and histologic features of PsO, mainly epidermal thickness, inflammatory cell infiltration, and keratinocyte hyperproliferation (42, 55)

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor Tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study

Metabolic parameters : For patients who also had improvements in blood glucose control, hemoglobin A1c levels may rise after stopping treatment

The inability to select between substrates may be linked to metabolic disorders